BACKGROUND: Using data from a relapse prevention study of duloxetine treatment for adults with major depressive disorder (MDD), we examined demographic- and illness-related variables to identify factors that may predict relapse of MDD. METHODS: Post-hoc analyses, using the Cox proportional hazards model, were performed on data from a study designed to compare the time to relapse of MDD in duloxetine- and placebo-treated patients. Patients received open-label duloxetine 60 mg/day during a 12-week acute phase, and those who met response criteria were randomly assigned to duloxetine 60 mg/day (N=136) or placebo (N=142) during a 26-week double-blind continuation phase. RESULTS: Significant predictors of relapse were VAS back pain score at entry >30, HAMD(17) total score at randomization >7, and geography (Europe vs. US). Four significant treatment-by-predictor interactions were identified: the SQ-SS pain subscale score at entry>median of 4, VAS overall pain score at entry >30, VAS overall pain score at entry>median of 26, and VAS overall pain score at randomization>median of 7. In the "greater severity" category, the risk of relapse was significantly lower for duloxetine-treated patients compared with placebo-treated patients. LIMITATIONS: These were post-hoc analyses. CONCLUSIONS: Higher levels of pain severity and depressive symptoms and a US geographical location were significant predictors of relapse in patients with MDD.
RCT Entities:
BACKGROUND: Using data from a relapse prevention study of duloxetine treatment for adults with major depressive disorder (MDD), we examined demographic- and illness-related variables to identify factors that may predict relapse of MDD. METHODS: Post-hoc analyses, using the Cox proportional hazards model, were performed on data from a study designed to compare the time to relapse of MDD in duloxetine- and placebo-treated patients. Patients received open-label duloxetine 60 mg/day during a 12-week acute phase, and those who met response criteria were randomly assigned to duloxetine 60 mg/day (N=136) or placebo (N=142) during a 26-week double-blind continuation phase. RESULTS: Significant predictors of relapse were VAS back pain score at entry >30, HAMD(17) total score at randomization >7, and geography (Europe vs. US). Four significant treatment-by-predictor interactions were identified: the SQ-SS pain subscale score at entry>median of 4, VAS overall pain score at entry >30, VAS overall pain score at entry>median of 26, and VAS overall pain score at randomization>median of 7. In the "greater severity" category, the risk of relapse was significantly lower for duloxetine-treated patients compared with placebo-treated patients. LIMITATIONS: These were post-hoc analyses. CONCLUSIONS: Higher levels of pain severity and depressive symptoms and a US geographical location were significant predictors of relapse in patients with MDD.
Authors: Elena Di Nasso; Alberto Chiesa; Alessandro Serretti; Diana De Ronchi; Claudio Mencacci Journal: Clin Drug Investig Date: 2011 Impact factor: 2.859
Authors: Henrik Walter; Quentin J M Huys; Isabel M Berwian; Julia G Wenzel; Leonie Kuehn; Inga Schnuerer; Erich Seifritz; Klaas E Stephan Journal: Sci Rep Date: 2022-07-01 Impact factor: 4.996
Authors: Peter Roy-Byrne; Mark D Sullivan; Cathy D Sherbourne; Daniela Golinelli; Michelle G Craske; Greer Sullivan; Murray B Stein Journal: Clin J Pain Date: 2013-09 Impact factor: 3.442
Authors: Andrew S Moriarty; Nicholas Meader; Kym Ie Snell; Richard D Riley; Lewis W Paton; Carolyn A Chew-Graham; Simon Gilbody; Rachel Churchill; Robert S Phillips; Shehzad Ali; Dean McMillan Journal: Cochrane Database Syst Rev Date: 2021-05-06
Authors: William H Roughan; Adrián I Campos; Luis M García-Marín; Gabriel Cuéllar-Partida; Michelle K Lupton; Ian B Hickie; Sarah E Medland; Naomi R Wray; Enda M Byrne; Trung Thanh Ngo; Nicholas G Martin; Miguel E Rentería Journal: Front Psychiatry Date: 2021-04-12 Impact factor: 4.157
Authors: Marloes M J G Gerrits; Patricia van Oppen; Stephanie S Leone; Harm W J van Marwijk; Henriëtte E van der Horst; Brenda W Penninx Journal: BMC Psychiatry Date: 2014-06-25 Impact factor: 3.630
Authors: Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier Journal: Int J Neuropsychopharmacol Date: 2018-02-01 Impact factor: 5.176